Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

BACKGROUND: Recombinant activated factor VII (rFVIIa, NovoSeven(®)) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX. OBJECTIVE: To review the evidence supporting the use of rFVIIa for the treatment of patients with congenital blee...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Johansson, Pär I, Ostrowski, Sisse R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2010
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2915535/
https://ncbi.nlm.nih.gov/pubmed/20689697
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller